Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Wayne Chen.
Oncotarget | 2018
Maher Albitar; Sucha Sudarsanam; Wanlong Ma; Shiping Jiang; Wayne Chen; Vincent Funari; Forrest Blocker; Sally Agersborg
Background The role of MET amplification in lung cancer, particularly in relation to checkpoint inhibition and EGFR WT, has not been fully explored. In this study, we correlated PD-L1 expression with MET amplification and EGFR, KRAS, or TP53 mutation in primary lung cancer. Methods In this retrospective study, tissue collected from 471 various tumors, including 397 lung cancers, was tested for MET amplification by FISH with a MET/centromere probe. PD-L1 expression was evaluated using clone SP142 and standard immunohistochemistry, and TP53, KRAS, and EGFR mutations were tested using next generation sequencing. Results Our results revealed that PD-L1 expression in non-small cell lung cancer is inversely correlated with EGFR mutation (P=0.0003), and positively correlated with TP53 mutation (P=0.0001) and MET amplification (P=0.004). Patients with TP53 mutations had significantly higher MET amplification (P=0.007), and were more likely (P=0.0002) to be EGFR wild type. There was no correlation between KRAS mutation and overall PD-L1 expression, but significant positive correlation between PD-L1 expression and KRAS with TP53 co-mutation (P=0.0002). A cut-off for the ratio of MET: centromere signal was determined as 1.5%, and 4% of lung cancer patients were identified as MET amplified. Conclusions This data suggests that in lung cancer both MET and TP53 play direct roles in regulating PD-L1 opposing EGFR. Moreover, KRAS and TP53 co-mutation may cooperate to drive PD-L1 expression in lung cancer. Adding MET or TP53 inhibitors to checkpoint inhibitors may be an attractive combination therapy in patients with lung cancer and MET amplification.
Journal of Clinical Oncology | 2018
Sucha Sudarsanam; Forrest Blocker; Sally Agersborg; Vincent Funari; Shiping Jiang; Wayne Chen; Josette Ragheb; Vladislav Chizhevsky; Maher Albitar
3022Background: DNA mismatch repair deficiency (dMMR) can be tested by immunohistochemistry (IHC) or microsatellite instability (MSI). While either IHC and MSI is adequate for establishing Lynch sy...
Cancer Research | 2018
Sally Agersborg; Christopher Mixon; Thanh T. Nguyen; Sramila Aithal; Forrest Blocker; Lawrence M. Weiss; Robert Gasparini; Shiping Jiang; Wayne Chen; Gregory Hess; Maher Albitar
PURPOSE While HER2 testing is well established in directing appropriate treatment for breast cancer, a small percentage of cases show equivocal results by IHC and FISH. Alternative probes may be used in equivocal cases. We present a single community-based institution9s experience in further evaluating these cases. PATIENTS AND METHODS Between 2014-2016, 4255 samples were submitted for HER2 amplification testing by alternative probes, TP53, RAI1, and RARA. Of patients tested by FISH, 505/3908 (12.9%) also had IHC data. RESULTS Most (73.9%) FISH equivocal cases remained equivocal after IHC testing. Duplicate testing by IHC using a different paraffin block resulted in poor reproducibility as 44% of IHC negative became equivocal and 40% of IHC equivocal became negative. Of the equivocal cases by IHC, 52.3% became positive by alternative FISH. However, 50.5% of cases equivocal by conventional FISH were classified as HER2 amplified by alternative probes. Most cases were positive by more than one probe; 78% of positive cases were positive by RAI1 and 73.9% by TP53. There was a significant difference between IHC and FISH alternative testing (P CONCLUSION The prevalence of double HER2 equivocal cases and the discrepancy between IHC and alternative FISH testing suggest that FISH alternative testing using both RAI1 and TP53 probes is necessary for conclusive classification. Due to the significant difference between IHC repeat testing, reflexing on IHC alone in this group of cases may not be reproducible. Because almost half of FISH equivocal cases converted to HER2 amplified upon alternative testing, clinical studies to determine benefit of anti-HER2 therapy in these patients is urgently needed. Citation Format: Sally Agersborg, Christopher Mixon, Thanh Nguyen, Sramila Aithal, Forrest Blocker, Lawrence Weiss, Robert Gasparini, Shiping Jiang, Wayne Chen, Gregory Hess, Maher Albitar. Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4524.
Breast Cancer Research and Treatment | 2018
Sally Agersborg; Christopher Mixon; Thanh T. Nguyen; Sramila Aithal; Sucha Sudarsanam; Forrest Blocker; Lawrence M. Weiss; Robert Gasparini; Shiping Jiang; Wayne Chen; Gregory Hess; Maher Albitar
PurposeWhile HER2 testing is well established in directing appropriate treatment for breast cancer, a small percentage of cases show equivocal results by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Alternative probes may be used in equivocal cases. We present a single community-based institution’s experience in further evaluating these cases.Patients and methodsBetween 2014 and 2016, 4255 samples were submitted for HER2 amplification testing by alternative probes, TP53, RAI1, and RARA. Of the patients tested by FISH, 505/3908 (12.9%) also had IHC data.ResultsMost (73.9%) FISH equivocal cases remained equivocal after IHC testing. However, 50.5% of equivocal cases were classified as HER2 amplified by alternative probes. Most cases were positive by more than one probe: 78% of positive cases by RAI1 and 73.9% by TP53. There was a significant difference between IHC and FISH alternative testing (p < 0.0001) among the equivocal cases by conventional FISH testing, 44% of IHC negative cases became positive while 36% of the positive IHC cases became negative by alternative FISH testing. Available data showed that 41% of patients were treated with palbociclib and were positive by alternative FISH.ConclusionThe prevalence of double HER2 equivocal cases and the discrepancy between IHC and alternative FISH testing suggest that FISH alternative testing using both RAI1 and TP53 probes is necessary for conclusive classification. Because almost half of FISH equivocal cases converted to HER2 amplified upon alternative testing, clinical studies to determine the benefit of anti-HER2 therapy in these patients are urgently needed.
Journal of Clinical Oncology | 2016
Wanlong Ma; Sally Agersborg; Steve Brodie; Ivan De Dios; Wayne Chen; Shiping Jiang; Maher Albitar
e23146Background: Companion diagnostic tests are currently recommended for the prescription of multiple therapeutic agents in oncology. Most of these companion tests are FDA-cleared kits. We compar...
Journal of Clinical Oncology | 2017
Maher Albitar; Sucha Sudarsanam; Wanlong Ma; Shiping Jiang; Wayne Chen; Vincent Anthony Funari; Sally Agersborg
Journal of Clinical Oncology | 2018
Maher Albitar; Sucha Sudarsanam; Wanlong Ma; Shiping Jiang; Wayne Chen; Vincent Funari; Forrest Blocker; Sally Agersborg
Journal of Clinical Oncology | 2017
Dennis P. O'Malley; Sucha Sudarsanam; Vladislav Chizhevsky; Wanlong Ma; Shiping Jiang; Wayne Chen; Vincent Anthony Funari; Sally Agersborg; Maher Albitar
Cancer Research | 2017
Maher Albitar; Sucha Sudarsanam; Wanlong Ma; Shiping Jiang; Wayne Chen; Vincent Funari; Steven Brodie; Sally Agersborg
Journal of Clinical Oncology | 2016
Vincent Anthony Funari; Wanlong Ma; Wayne Chen; Shiping Jiang; Sally Agersborg; Maher Albitar